Sadly not the #blisterwalk this year
Not in Chicago – Breast cancer has been a hot topic again on several fronts after a bit of a lull on the R&D front.
Writing about such trials across ESMO Breast, ASCO and the second AACR meeting is all very well, but what about some KOL commentary and reactions to some of the data we get to see?
If this has been a burning question for you, this is a handy article to catch up on. Of course, to be clear – not all the trials will be positive or biomarker analysis helpful, so here we tackle the issue and look at what’s what though the lens of a specialist…
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the ESMO Breast, ASCO and second AACR meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
Checkpoint fight at the Alamo in San Antonio? Say it ain’t so!
This is the $64M question that will be on many people’s mind after seeing two SABCS headlines today:
“Neoadjuvant and Adjuvant Treatment with Pembrolizumab Improves Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancerwith Lymph Node Involvement.”
“Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer.”
In order to answer the question fairly, there are plenty of critical points we can look at in order to address it.
That’s the topic of today’s post in a nutshell… and yes, we do come to a firm conclusion.
Curious to find out more about the latest breast cancer data and get a heads up on additional insights from our SABCS commentary?Subscribers can log-in or you can click to gain access to BSB Premium Content.
Morning, morning, where’s the strong hot java today?
Barcelona – Here we are on the third day of ESMO 2019 and this is where many presenters and attendees (especially international ones) start to hit the wall with a combination of tiredness, sore feet, late nights, lack of coffee, and jet lag all combine to create a perfect storm of exhaustion.
No matter – the conference schedule marches on!
After the craziness of posting not one, but three, extensive long form posts with commentary and analysis yesterday, I’m delighted to only have to worry about managing the daily highlights today. We’ve also been busy conducting interviews, running round the poster halls and listening to some elegant science talks as well.
If you’ve missed the rest of our ESMO19 coverage, it’s building up nicely so far on this magazine page – do check it out and take your pick of topics to browse.
There are some key phase 3 readouts expected in breast cancer alone, plus a raft of Developmental Therapeutic updates to ponder as well.
As usual, we start off with some known highlights and then move on to updating on oncologic developments that catch our attention through the day.
To learn more from our latest oncology conference insights and get a heads up on our latest ESMO Coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.